RT Book, Section
A1 Koonce, Stephanie
A1 McLaughlin, Sarah A.
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145760904
T1 Survivorship Issues in Breast Cancer
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK hemonc.mhmedical.com/content.aspx?aid=1145760904
RD 2024/04/24
AB Improvements  in  diagnosis  and  advances  in  targeted  therapies  have  contributed  to  the  increasing  numbers  of  breast  cancer  survivors.  The  most  recent  estimate  by  the  Surveillance  Epidemiology  and  End  Results  (SEER)  database  estimates  nearly  2.8  million  breast  cancer  survivors  alive  as  of  2013,  an  increase  from  previous  estimates.1  As  the  numbers  of  survivors  have  increased  and  as  many  of  those  survivors  are  living  decades  beyond  their  treatment,  issues  affecting  survivorship  and  overall  quality  of  life  (QOL)  have  moved  to  the  forefront  of  breast  cancer  research.  Identification  and  classification  of  the  persistent  and  late  consequences  of  breast  cancer  treatment  have  become  critical  endpoints  in  many  newly  developed  clinical  trials.  In  fact,  with  the  input  of  patient  advocates  contemporary  clinical  trial  development  frequently  includes  assessment  of  outcomes  equally  according  to  efficacy  and  anticipated  impact  on  future  QOL.